INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.450
+0.150 (11.54%)
At close: Jun 18, 2026, 4:00 PM EDT
1.410
-0.040 (-2.74%)
After-hours: Jun 18, 2026, 7:46 PM EDT
INmune Bio Revenue
In the year 2025, INmune Bio had annual revenue of $50.00K with 257.14% growth.
Revenue (ttm)
$50.00K
Revenue Growth
+257.14%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
38.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 50.00K | 36.00K | 257.14% |
| Dec 31, 2024 | 14.00K | -141.00K | -90.97% |
| Dec 31, 2023 | 155.00K | -219.00K | -58.56% |
| Dec 31, 2022 | 374.00K | 193.00K | 106.63% |
| Dec 31, 2021 | 181.00K | 170.00K | 1,545.45% |
| Dec 31, 2020 | 11.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aligos Therapeutics | 4.71M |
| CervoMed | 2.09M |
| Nutriband | 1.80M |
| Daré Bioscience | 1.16M |
| ABVC BioPharma | 797.92K |
| Lisata Therapeutics | 170.00K |
| Actinium Pharmaceuticals | 90.00K |
INMB News
- 4 days ago - INmune Bio Transcript: AGM 2026 - Transcripts
- 17 days ago - INmune Bio reports positive MRI data in Phase 2 Alzheimer’s trial - TheFly
- 18 days ago - INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial - GlobeNewsWire
- 18 days ago - INmune Bio Slides: Corporate presentation - Filings
- 5 weeks ago - INmune Bio publishes MINDFuL trial results in NPJ Dementia - TheFly
- 5 weeks ago - INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform - GlobeNewsWire
- 5 weeks ago - INmune Bio receives fast track designation from FDA for XPro - TheFly
- 5 weeks ago - INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease - GlobeNewsWire